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R-roscovitine (CYC202) alleviates renal cell proliferation in
nephritis without aggravating podocyte injury.
Background. Cyclin-dependent kinase (CDK) inhibition is
a new therapeutic approach to proliferative glomerulonephri-
tides. CDK2 is required for G1/S transition and DNA synthesis
and is inhibited by CYC202 (R-roscovitine). Since podocytes
express CDK2 in nephritis and since loss of podocytes con-
tributes to glomerulosclerosis, the rationale of the present study
was to test whether CDK2 inhibition is safe in instances of
podocyte injury.
Methods. Rats with passive Heymann nephritis, a model of
membranous glomerulonephritis, were treated (day 3 to 30)
with vehicle, low (25 mg/kg/day), or high (50 mg/kg/day) doses
of CYC202.
Results. On day 27, blood pressure was normal in nephritic
controls and was dose-dependently reduced by CYC202. Uri-
nary albumin excretion did not differ between the groups on
days 9, 16, 23, and 30. To investigate podocyte injury, we as-
sessed the glomerular de novo expression of desmin, which was
markedly up-regulated in almost all passive Heymann nephri-
tis glomeruli but was not significantly different between the
three groups. No tubulointerstitial de novo expression of desmin
or alpha-smooth muscle actin (a-SMA), or tubulointerstitial
monocyte/macrophage infiltration was noted in any group.
Biologic activity of CYC202 was evident in the form of a
dose-dependent decrease in the number of glomerular and
tubulointerstitial mitotic figures as compared to vehicle alone.
Glomerular immunostaining for cyclin D1, a marker for G0 to
G1 transition, was significantly decreased in CYC202 treated
groups at day 9.
Conclusion. Whereas inhibition of CDKs by CYC202 re-
duced intrarenal cell proliferation in passive Heymann nephritis
it did not aggravate podocyte damage, suggesting that this novel
therapeutic approach is safe in renal diseases characterized by
podocyte injury.
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Glomerulonephritides and systemic immunologic dis-
eases account for 20% to 25% of terminal renal
failures in most Western countries. Many progressive
immune-mediated glomerular diseases are characterized
by mesangial proliferative changes and would thus po-
tentially benefit from therapy with a cell cycle inhibitor.
However, all of these glomerular diseases, as well as
metabolic glomerular diseases such as diabetic nephropa-
thy, appear to advance to glomerular scaring through
secondary podocyte damage [1–3]. Other progressive
glomerulonephritides do not exhibit mesangial prolifera-
tive changes but rather primary podocyte injury. A classic
disease of this group is membranous glomerulonephritis,
where an (auto) immune process leads to podocyte dam-
age without significant changes inside the glomerular tuft.
Primary or secondary podocyte damage determines the
rate of glomerular and subsequent renal tubulointerstitial
scaring [3].
The particular role of the podocyte as a final com-
mon pathway of glomerular scaring has traditionally been
explained by the terminal differentiation of these cells
and the assumption that a damaged podocyte can not
be replaced, resulting in areas of bare glomerular base-
ment membrane (GBM), which then fuse with the outer
Bowman’s capsule and thereby generate a first adhesion
between glomerular tuft and capsule. Such adhesions are
viewed as the starting point of segmental and ultimately
global glomerulosclerosis [3, 4].
Recently, the view of the podocyte as a terminally dif-
ferentiated cell has been challenged. Observations of
rare, yet definitive podocyte DNA synthesis and mi-
toses in glomerulonephritis, and bi- (multi-) nucleation
rather than increased cell numbers, suggest that injured
podocytes in principle possess the ability to replicate but
instead engage in a defective cell cycle with acytokinetic
mitosis [5]. Normal and/or injured podocytes contain high
levels of the cyclin-dependent kinase (CDK) inhibitors
p21 and p27 [6, 7], which would prevent cell cycle pro-
gression. However, they have also been demonstrated
to express CDK2, a promoter of cell cycle progression,
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during passive Heymann nephritis [7], a model of hu-
man membranous glomerulonephritis in rats [8]. This
model is therefore of particular use to study the effects of
CDK2 inhibition in podocyte disease, given the concern
that CDK2 inhibition might impair the little adaptive re-
sponse that podocytes can exhibit and thereby aggravate
the development of glomerulosclerosis. However, CDK2
inhibition in passive Heymann nephritis might also be
beneficial. Very recent data show that engagement of
podocytes in the cell cycle may alter their adhesive prop-
erties in such a way that they are lost in the urine [with all
the potential consequences described above (i.e., denuda-
tion of basement membrane and adhesion formation)]
[9]. In this scenario, it might even be beneficial to prevent
the podocyte from engaging in the cell cycle. The aim of
our study was therefore to determine the effects of cur-
rently employed therapeutic doses of a CDK2 inhibitor,
R-roscovitine (CYC202), in passive Heymann nephritis.
CYC202, a purine analogue, inhibits the activity of CDK2
but also of other CDKs, including CDK1 (cdc2), CDK5,
CDK7, and CDK9, by binding to their adenosine triphos-
phate (ATP) binding pocket [10]. However, the affinity
of CYC202 to the different CDKs is variable with inhibi-
tion constants (IC)50 of 0.1 lmol/L for CDK2/cyclin E, 0.7
lmol/L for CDK2/cyclin A, 0.5 lmol/L for CDK7/cyclin
H, 0.84 lmol/L for CDK9/cyclin T1, and 2.7 lmol/L for
CDK1/cyclin B [11].
METHODS
Experimental design
Male rats (Sprague-Dawley, Charles River Wiga
GmbH, Sulzfeld, Germany), weighing 180 to 210 g at the
start of the experiment, were used in the experiments.
Rats were housed in cages under conditions of constant
temperature (22◦C) and humidity (50%), with a 12-hour
dark/light cycle. The animals had free access to tap water
and standard rat chow. Passive Heymann nephritis was
induced on day 0 by intravenous injection of 0.3 mL of
sheep anti-Fx1A antibody per rat, prepared as described
previously [8]. All animal experiments were approved by
the local review boards.
Treatment with CYC202 was started on day 3, in order
to avoid interference with the induction phase of passive
Heymann nephritis, and continued until day 30. Treat-
ment consisted of once-daily oral gavage of CYC202 un-
til day 10. CYC202 was dissolved in 30 mmol/L HCl and
stirred with a magnetic stirrer until dissolution. After day
10, treatment was switched to daily intraperitoneal in-
jections. The vehicle used here was dimethyl sulfoxide
(DMSO) (ICN Biomedicals, Aurora, OH, USA). Three
groups of rats were studied: group I, nephritic untreated
group (N = 10) (animals received vehicle alone); group
II, nephritic low dose treatment group (N = 10) (ani-
mals were treated once daily with 25 mg CYC202/kg/day);
and group III, nephritic high dose treatment group (N =
10) (animals were treated once daily with 50 mg
CYC202/kg/day).
To determine urinary albumin excretion, 24-hour urine
collections were performed in metabolic cages on days 9,
16, 23, and 30 after disease induction.
Renal biopsies for histologic evaluation were obtained
on day 9 by intravital biopsy and during postmortem on
day 30 after disease induction. The thymidine analogue 5-
bromo-2′deoxyuridine (BrdU) (100 mg/kg body weight)
(Sigma Chemical Co., St. Louis, MO, USA) was injected
intraperitoneally at 4 hours before sacrifice on day 30.
All rats were sacrificed under isoflurane anesthesia and
blood was collected by puncture of the vena cava infe-
rior 5 hours after administering the last dose of CYC202.
Kidneys were harvested and prepared for histologic
examination.
Renal morphology
Tissue for light microscopy and immunoperoxidase
staining was fixed in methyl Carnoy’s solution [12] and
embedded in paraffin. Four micrometer sections were
stained with the periodic acid-Schiff (PAS) reagent and
counterstained with hematoxylin.
Using a 400-fold magnification of the PAS-stained sec-
tions, the total number of mitoses within the glomeru-
lar tuft (extrapolated to mitoses per 100 glomerular cross
sections) was counted. To determine this, between 20 and
100 glomerular profiles were evaluated per specimen on
day 9 and between 100 and 190 glomerular profiles were
evaluated on day 30.
In addition, the number of mitoses in the tubulointer-
stitium was evaluated using a grid composed of 100 fields
at a magnification of 400-fold, so that every field corre-
sponded to an area of 0.0625 mm2. One hundred grid
fields in the renal cortical tubulointerstitium were ana-
lyzed and mean counts per kidney were obtained.
Electron microscopy was performed following stan-
dard protocols [13]. Blocks of renal tissue (1 mm3) were
fixed in a solution of 2% formaldehyde and 2.5% glu-
taraldehyde according to Karnovsky’s method, with ca-
codylate buffer (0.2 mol/L, pH 7.4). After fixation, the
samples were dehydrated and embedded in epoxy resin
(glycide ether 100) (Serva, Heidelberg, Germany). Sec-
tions were cut and stained with toluidine-blue for light
microscopy prescreening. Ultrathin sections were then
cut at 80 to 100 nm, stained with uranyl acetate and lead
citrate, and viewed and photographed in a Philips TEM
400 transmission electron microscope. For evaluation of
slit numbers per length of GBM, images were obtained
from random areas, enlarged 13,000-fold and the number
of filtration-slits per GBM length was measured.
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Immunoperoxidase staining
Four micrometer sections of methyl Carnoy’s fixed
biopsy tissue were processed by an indirect immunoper-
oxidase technique [12]. Primary antibodies included [14]:
(1) a monoclonal IgG1 antibody (clone D33) against hu-
man muscle desmin (1:100) (Dako, Glostrup, Denmark);
(2) cyclin D1, a rabbit polyclonal antibody (bcl-1 Ab-3)
(1:100) (Lab Vision, Fremont, CA, USA) raised against
the C-terminal portion of cyclin D1 of rat origin [15];
(3) ED1 (1:500)(Serotec, Oxford, UK), a monoclonal
IgG antibody to a cytoplasmic antigen present in mono-
cytes, macrophages and dendritic rat cells; (4) a mono-
clonal IgG antibody (clone 1A4) to an NH2-terminal syn-
thetic decapeptide of human alpha-smooth muscle actin
(a-SMA) (1:500) (Dako); (5) BU-1, a monoclonal anti-
body against bromo-deoxyuridine (Amersham, Braun-
schweig, Germany); (6) proliferating cell nuclear antigen
(PCNA) (Ab-1) (clone PC10) (1:1000) (Oncogene Sci-
ence Inc., Uniondale, NY, USA) a mouse monoclonal
IgG antibody that reacts with the human PCNA, which
is expressed in a cell cycle dependent manner [16]; and
(7) WT1 (F-6) (1:300) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), a mouse monoclonal IgG1 that reacts
with the WT1 antigen on podocytes and epithelial cells
of the Bowman capsule.
Desmin staining was evaluated using a point counting
method. For this, a grid composed of 121 dots was super-
imposed on at least 20 glomeruli (magnification 600-fold)
and the percentage of dots overlying stained areas were
counted. Similarly, tubulointerstitial a-SMA staining was
evaluated by superimposing the grid on at least 50 tubu-
lointerstitial grid fields measuring 0.027 mm2 each.
The glomerular expression of cyclin D1 was analyzed
on days 9 and 30. Thirty glomerular cross sections were
evaluated per sample and the results were expressed as
the mean number of nuclei/cells staining positively per
30 glomerular cross sections. To obtain total counts of
infiltrating monocytes/macrophages in the renal cortical
tubulointerstitium, 100 grid fields (see above) were ana-
lyzed and mean counts per kidney were obtained.
To obtain mean numbers of proliferating (PCNA+)
cells in glomeruli on day 9 at least 20 consecutive cross
sections of glomeruli (magnification 600-fold) were eval-
uated and mean values per glomerular cross sections were
calculated. In addition, we determined the number of
PCNA+ cells at the edge of the glomerular tuft, presumed
to represent PCNA+ podocytes.
To further evaluate whether these cells represented
proliferating podocytes, we performed double stainings
for PCNA and the podocyte specific marker WT1 on day
30. First, sections were stained for WT1 using a blue al-
kaline phosphatase substrate kit (Vector Laboratories,
Burlingame, CA, USA) generating a blue color product.
On the next day, proliferating cells were stained with our
PCNA antibody using an immunoperoxidase procedure,
including 3-amino-9-ethylcarbazole (AEC) generating a
red color product. Cells were identified as proliferating
podocytes if they showed both positive nuclear stainings
for PCNA and WT1, generating a blueish-purple color
product.
Negative controls for all of the immunohistochemical
analyses included substitution of the primary antibody
with normal IgG from the same species as the primary an-
tibody at a similar concentration. Evaluation of all slides
was performed by an investigator who was unaware of
the origin of the slides.
Miscellaneous measurements
Blood pressure was measured by tail-cuff plethysmog-
raphy on day 27 in conscious rats using a programmed
sphygmomanometer (BP-981) (Softron, Tokyo, Japan).
For each animal, at least three consecutive measurements
were performed.
CYC202 serum levels were determined on day 30
by mass spectroscopy (MS) (Quattro Ultima, Wa-
ters/Micromass UK Ltd., Manchester, UK) with serum
extraction carried out following total protein precipita-
tion. CYC202 serum levels were determined from a stan-
dard calibration line over the linear range 0.01 lmol/L to
7.2 lmol/L with appropriate sample dilutions with con-
trol rat serum (Wistar, mixed gender) (Harlan Seralab
UK, Ltd., Loughborough, UK) made where necessary.
Creatinine was measured in serum using an au-
toanalyzer (Beckman Instruments GmbH, Mu¨nchen,
Germany).
Urinary albumin excretion was determined by using a
sandwich enzyme-linked immunosorbent assay (ELISA)
(Nephrat) (Exocell Inc., Philadelphia, PA, USA).
Statistical analysis
All values are expressed as mean ± SD or as individ-
ual data. Statistical significance (defined as P < 0.05) was
evaluated using one-way analysis of variance (ANOVA)
with modified t test performed with the Bonferroni cor-
rection [17].
RESULTS
Animal behavior, body weight, and CYC202 serum levels
Four rats died (1 to 2 in each group) during the first
10 days of the experiment due to technical failure. All
other rats were active and appeared healthy, and did not
develop evidence of peritonitis, ascites, or diarrhea during
the study.
Prior to disease induction, there were no significant
differences between the three groups in terms of body
weight. Rats from all groups gained weight in the next
30 days, although the body weights of the vehicle-only–
treated rats were moderately higher than those of low-
dose or high-dose CYC202-treated rats at each time point
Milovanceva-Popovska and Kunter et al: CDK Inhibition in Heymann nephritis 1365
Table 1. Body weights, CYC202 serum levels, serum creatinine, and
blood pressures of the experimental groups following the induction of
passive Heymann’s nephritis
Nephritic + Nephritic +
Nephritic + 25 mg/kg/day 50 mg/kg/day
vehicle CYC202 CYC202
Body weight g (N = 9) (N = 9) (N = 8)
Day 7 202 ± 9 199 ± 11 197 ± 11
Day 14 255 ± 15 243 ± 21 225 ± 17
Day 21 288 ± 18 274 ± 23 249 ± 18
Day 28 304 ± 15 290 ± 22 270 ± 13a
CYC202 serum <0.01 5 ± 2 15 ± 8
concentration
(day 30) lmol/L
Serum creatinine 35 ± 5 35 ± 8 45 ± 10a,b
(day 30) lmol/L
Mean blood pressure 92 ± 6 85 ± 6a 76 ± 4a
(day 27) mm Hg
aP < 0.05 versus group receiving vehicle; bP < 0.05 versus group receiving 25
mg/kg/day CYC202.
(Table 1). At day 30, the body weight of the high-dose
CYC202-treated group was significantly lower as com-
pared to the vehicle-only–treated group.
Determination of CYC202 serum levels on day 30 re-
vealed a mean level of 4.9 lmol/L in the rats receiving
25 mg/kg/day and threefold higher levels in the group
receiving 50 mg/kg/day (Table 1).
Renal function, proteinuria, and blood pressure
Serum creatinine values remained within the normal
range in vehicle-treated and low-dose CYC202 rats. In the
high-dose CYC202-treated group serum creatinine was
significantly increased as compared to the other groups
on day 30, although it still remained in the normal range
(Table 1).
As shown in Figure 1, urinary albumin excretion
peaked on day 9, when it was about 70-fold elevated over
the normal range, and then decreased until day 16 in all
three groups. From day 16 until the end of the study uri-
nary albumin excretion remained 30-fold elevated over
controls. No statistically significant differences between
the groups were noted at any of the time points measured.
Mean systolic blood pressures in nephritic rats receiv-
ing vehicle were within the normal range on day 27
(Table 1). Treatment of nephritic rats with CYC202 re-
sulted in a dose-dependent decrease of mean systolic
blood pressure (Table 1).
Morphologic studies
Glomerular changes. Examination of PAS-stained
sections obtained from kidneys on days 9 and 30 revealed
no evidence for focal or global glomerulosclerosis in any
specimen (Fig. 2A).
Ultrastructural examinations of kidney specimens ob-
tained at day 30 following passive Heymann’s nephri-
tis induction revealed typical changes as previously
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Fig. 1. Urinary albumin excretion in rats with passive Heymann
nephritis on days 9, 16, 23, and 30 receiving either vehicle or CYC202
from day 3 to 30 after disease induction. The normal albuminuria deter-
mined in five healthy rats of the same age, gender, and weight was 0.11
± 0.04 mg/24 hours. Rats receiving vehicle-only () (N = 9); rats receiv-
ing 25 mg/kg/day of CYC202 ( ) (N = 9); rats receiving 50 mg/kg/day
of CYC202 () (N = 8).
reported in passive Heymann’s nephritis. These changes
included frequent electron-dense deposits within the
basement membrane and the subepithelial space, seg-
mental flattening and fusion of podocyte foot pro-
cesses, as well as hypertrophy of the podocyte cell body
(Fig. 2B). For quantification of podocyte damage, the
number of filtration slits per glomerular basal membrane
length was evaluated in three high-dose CYC202-treated
rats (26 randomly chosen areas, 319 slits) and three con-
trol animals (21 randomly chosen areas, 245 slits). In un-
treated rats, 1.19 ± 0.2 slits were counted per micrometer
of GBM vs. 1.07 ± 0.07 per micrometer GBM in high-
dose CYC202 animals (P = NS) (data not shown). In
summary, we were unable to identify any ultrastructural
differences between rats that had received control com-
pound, low doses, or high doses of CYC202/roscovitine
regarding both the incidence as well as the severity of
glomerular lesions.
To specifically investigate glomerular injury in the
rats with passive Heymann’s nephritis, we assessed the
glomerular de novo expression of desmin, which in pas-
sive Heymann’s nephritis can serve as a specific marker
of podocyte injury [18]. As expected, desmin expression
was markedly up-regulated in almost all glomeruli on
days 9 and 30 (Fig. 3A and B), confirming earlier ob-
servations [18]. However, we did not detect any signifi-
cant difference between the CYC202-treated groups and
the animals treated with vehicle-only at either time point
(Fig. 3C). Of note, if at all, desmin expression tended
to be lower on day 30 in the nephritic groups receiving
CYC202. Glomerular de novo expression of a-SMA, a
marker of activated mesangial cells [19], was not observed
in any specimen (data not shown).
To assess the biologic activity of CYC202 in vivo in
addition to measuring serum levels (see above), we next
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Fig. 2. Morphologic changes in rats with passive Heymann’s nephri-
tis on day 30 treated with high-dose CYC202. (A) Periodic acid-Schiff
(PAS) staining. Regular glomerular structure without signs of glomeru-
losclerosis (magnification ×600). (B) Transmission electron microscopy.
Ultrastructural changes included widespread electron-dense deposits
within the basement membrane and the subepithelial space (arrows),
irregular basement membrane protrusions, as well as flattening and fu-
sion of podocyte foot processes (magnification ×13,000). Similar obser-
vations were made in rats with low-dose CYC202 or vehicle.
investigated cell proliferation and the expression of cyclin
D1.
Compared to the vehicle-only group, treatment with
low-dose CYC202 decreased the number of glomerular
mitotic figures at day 30 by 22% and by 61% in the high-
dose group (Fig. 4), a statistically significant reduction.
Cell proliferation appeared to be equally reduced in both
mesangial and glomerular endothelial cells in CYC202-
treated animals as compared to the vehicle group, judged
by the location of mitotic figures in PAS-stained sections
(data not shown). Cell proliferation was also assessed by
counting of BrdU-positive glomerular cells. It was sig-
nificantly lower in the high-dose CYC202-treated group
when compared to the vehicle-only–treated group (3.3 ±
2.4 vs. 19.2 ± 8.3 BrdU-positive nuclei/100 glomeruli
in the high-dose vs. vehicle group, respectively) (P <
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Fig. 3. Glomerular expression of desmin. (A) In vehicle-treated
nephritic rats on day 30, desmin expression in glomeruli is widespread
and mostly locates to podocytes (magnification ×400). (B) In nephritic
rats receiving high-dose CYC202, the expression of desmin on day 30 is
similar (magnification ×400). (C) Quantitative assessment of glomeru-
lar desmin expression in rats with passive Heymann’s nephritis receiving
either vehicle or CYC202 from day 3 to 30 after disease induction. All
differences were not significant. Rats receiving vehicle only () (N =
9); rats receiving 25 mg/kg/day of CYC202 ( ) (N = 9); rats receiving
50 mg/kg/day of CYC202 () (N = 8).
0.05). Reduced glomerular cell proliferation in CYC202-
treated animals was not due to changes in glomerular
monocyte/macrophages, the counts of which remained in
the normal range in all specimens (data not shown).
Since mitoses and BrdU incorporation in cells at the
edge of the glomerular tuft (i.e., podocytes), occurred
too infrequently on day 9 of passive Heymann’s nephritis
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Fig. 4. Quantitative evaluation of cell proliferation (as defined by
counts of mitotic figures) in glomeruli and the tubulointerstitium of rats
with passive Heymann’s nephritis receiving either vehicle or CYC202
from day 3 to 30 after disease induction. ∗P < 0.05 versus nephritic
rats receiving vehicle alone. Rats receiving vehicle only () (N = 9);
rats receiving 25 mg/kg/day of CYC202 ( ) (N = 9); rats receiving 50
mg/kg/day of CYC202 () (N = 8).
to be quantified, we also stained the sections for PCNA.
The number of PCNA+ cells per glomerular cross section
and, more important, at the edge of the glomerular tuft
decreased significantly on day 9 in both low- and high-
dose CYC202-treated groups (Table 2).
Additional double stainings for the podocyte-specific
WT1 and PCNA on day 30 showed no significant dif-
ference in low-dose or high-dose–treated animals when
compared to untreated animals (0.38 ± 0.3 vs. 0.52 ±
0.4 positive cells/glomerulus in the low-dose group com-
pared to untreated animals and 0.9 ± 0.6 vs. 0.52 ± 0.4
positive cells/glomerulus in the high-dose animals when
compared to untreated animals).
Cyclin D1 expression, a marker of cell entry into the
G1 phase of the cell cycle, was observed in some glomeru-
lar cells in a cytoplasmic or nuclear location (Fig. 5A and
B). This is consistent with observations in normal rat kid-
Table 2. Proliferating cell nuclear antigen positive (PCNA+) cells on
day 9
Nephritic + Nephritic +
Nephritic + 25 mg/kg/day 50 mg/kg/day
vehicle CYC202 CYC202
Group (N = 9) (N = 9) (N = 8)
Number of PCNA+ 6.7 ± 1.8 3.9 ± 1.2a 3.8 ± 0.8a
cells/glomerular
cross section
Number of PCNA+ 2.3 ± 0.7 1.1 ± 0.4a 0.8 ± 0.5a
cells at the edge of
the glomerular tuft/
glomerular cross section
aP < 0.05 versus group receiving vehicle.
ney in vitro, where cyclin D1 localized to the cytoplasm
and was shifted to the nucleus during cell proliferation
[20]. The glomerular expression of cyclin D1–positive
cells decreased significantly on day 9 in both groups re-
ceiving CYC202. This difference did not persist on day 30
(Fig. 5C), suggesting that at this stage CYC202 no longer
prevented entry of cells into the cell cycle, yet still in-
terfered with completion of the cell cycle, as shown by
persistently reduced mitosis rates and PCNA positivity
(Fig. 4) (Table 2).
Tubulointerstial changes. No tubulointerstitial dam-
age occurred in any group of rats as judged by PAS stain-
ing of the sections and by the absence of de novo inter-
stitial a-SMA and desmin expression (data not shown)
(i.e., two markers of myofibroblast transformation or ep-
ithelial transdifferentiation [21]).
Further evidence of a biologic effect of CYC202 was
obtained by assessing tubulointerstitial mitosis rates. In
comparison to vehicle-treated nephritic rats, the number
of mitotic figures in the tubulointerstitium decreased in
a statistically significant manner with low-dose CYC202
treatment at day 9 and with high-dose CYC202 treatment
at days 9 and 30 (Fig. 4). Similar data were obtained,
when mitotic rates were determined within the tubular
cells only (data not shown). Reduced tubulointerstitial
cell proliferation in low-dose and high-dose CYC202-
treated rats was also confirmed by quantification of
BrdU-positive nuclei (high dose 32 ± 7 BrdU-positive
nuclei per 100 grids; low dose 52 ± 20; vehicle 84 ± 34)
(P < 0.05). Tubulointerstitial monocyte/macrophage
counts remained unaffected by CYC202 treatment on day
9, but were significantly lower in the high-dose CYC202
group as compared to vehicle-treated rats on day 30
(Fig. 6).
DISCUSSION
CDKs are key regulators of the cell cycle, which be-
come active when they associate with their respective cy-
clin subunits, proteins that are present only at specific
stages of the cell cycle [22, 23]. Of the CDKs inhibited by
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Fig. 5. Immunostaining for cyclin D1 in rats with passive Heymann’s
nephritis receiving either vehicle or CYC202 from day 3 to 30 after
disease induction. (A) In vehicle-treated nephritic rats on day 9, cyclin
D1 is expressed mostly in the cytoplasm (magnification ×400). (B) In
nephritic rats receiving high-dose CYC202, the expression of cyclin D1
on day 9 is qualitatively similar as in rats receiving vehicle, although
quantitatively reduced (magnification ×400). (C) Quantitative assess-
ment of glomerular cells staining positive for cyclin D1. ∗P < 0.05 versus
nephritic rats receiving vehicle alone. Rats receiving vehicle only () (N
= 9); rats receiving 25 mg/kg/day of CYC202 ( ) (N = 9); rats receiving
50 mg/kg/day () of CYC202 (N = 8).
CYC202 [11], CDK2 is clearly expressed and regulated
in passive Heymann’s nephritis (see above) and its inhi-
bition likely constituted the major effect of CYC202 in
the present study. It is possible, but at the plasma levels
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Fig. 6. Tubulointerstitial counts of monocytes/macrophages (ED1-
positive cells) in rats with passive Heymann’s nephritis receiving either
vehicle or CYC202 from day 3 to 30 after disease induction. ∗P < 0.05
versus nephritic rats receiving vehicle alone. Rats receiving vehicle only
() (N = 9); rats receiving 25 mg/kg/day of CYC202 ( ) (N = 9); rats
receiving 50 mg/kg/day of CYC202 () (N = 8).
achieved less likely, that CDK1 was also affected and con-
tributed to the activity of CYC202. In cell culture CDK1 is
expressed in podocytes and is down-regulated by stretch-
ing or complement-mediated damage of the cells [24, 25].
Very recent data also describe CDK1 overexpression in
passive Heymann’s nephritis [26]. Effects on CDK5 are
unlikely to contribute to our observations, since CDK5
mostly acts in the central nervous system [27], although
very recent data suggest that CDK5 may play a role in
podocyte differentiation during embryogenesis [abstract;
Hiromura K, et al, J Am Soc Nephrol 13:32A, 2002]. Fi-
nally, CYC202 is also known to inhibit CDK7 and CDK9,
CDKs involved in the phosphorylation of RNA poly-
merase II during transcription. Although currently no
data exist on the expression of these two CDKs in pas-
sive Heymann’s nephritis, there is evidence that both are
expressed in the kidney [28, 29]. A reduced transcrip-
tion rate resulting from CYC202-mediated inhibition of
CDK7 and/or CDK9 would correlate with the lowering
of cyclin D1 levels observed in this study. The impact of
CYC202 would thus depend on the stage of the cell cycle
of a particular cell at the time of exposure to the drug.
In a model of mesangioproliferative glomerulonephri-
tis in rats, where the normally low level of glomerular
CDK2 expression is markedly up-regulated, reducing the
activity of CDK2 with roscovitine was beneficial, in that
it decreased glomerular hypercellularity and matrix pro-
tein accumulation [30]. In contrast to mesangioprolifer-
ative changes, which are frequent in human glomerular
disease, very few diseases are characterized by podocyte
proliferation. These include the cellular variant of fo-
cal segmental glomerulosclerosis (FSGS) [31], collaps-
ing glomerulopathy [32], and human immunodeficiency
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virus (HIV)-associated nephropathy [32]. In the large ma-
jority of podocyte-related diseases, such as classic FSGS,
membranous nephropathy, and minimal change disease,
podocytes do not proliferate [33] although they may over-
express cell cycle regulatory proteins, including CDK2,
and as a result enter the cell cycle [7, 34]. As discussed
previously, in such instances the consequences of CDK2
inhibition for the podocyte might range from detrimental
to beneficial.
The major finding of the present study was that CDK2
inhibition did not aggravate the course of the disease
in a model bearing close similarity to human membra-
nous glomerulonephritis. As assessed by albuminuria and
signs of podocyte damage, no augmentation was noted
in rats receiving either low- or high-dose CYC202, de-
spite the fact that podocytes overexpress CDK2 in passive
Heymann’s nephritis [7, 34]. Our study thereby resolves
an important safety concern, since primary or secondary
podocyte damage is widespread in progressive glomeru-
lar disease [1–3]. On the other hand, despite a theoretic
possibility (see above), we did not obtain clear evidence
for a beneficial action of CYC202 on the course of pas-
sive Heymann’s nephritis as judged by proteinuria. In
contrast, in a model with prominent podocyte prolifera-
tion (i.e., collapsing glomerulopathy in mice), high-dose
CYC202 (75 mg/kg body weight for 20 days) significantly
improved glomerular lesions as compared to the control
group exhibiting progressive disease [35].
In our study we also observed a reduction of systemic
blood pressure in nephritic rats receiving CYC202. Tran-
siently reduced blood pressure has also been noted in
healthy dogs receiving high dose (500 mg/m2) CYC202
(Cyclacel Ltd., Dundee, UK, unpublished data). Whether
such a potentially beneficial side effect of CYC202 also
occurs at therapeutic dosages in humans is currently un-
known. Under the particular circumstances of the present
study the dose-dependent blood pressure reduction (i.e.,
hemodynamic mechanisms), likely accounted for the ob-
servation of a mildly increased serum creatinine on day
30 in the high-dose CYC202 group since no morphologic
evidence for irreversible renal damage was present. How-
ever, a possible toxicity of the drug cannot be ruled out
with certainty.
Although we did not determine glomerular CDK2 ac-
tivity directly, a number of observations suggest that
CYC202 was active in vivo. First, serum levels in the
present study obtained at 5 hours after the last CYC202
dose equated to 4.6 and 14.8 lmol/L, respectively, which
corresponds to levels of the drug required for biologic
activity (5 to 20 lmol/L). Second, CYC202 reduced both
glomerular and tubulointerstitial cell proliferation (how-
ever, without leading to dectable pathology through this
effect at least over the time course of the experiment).
Third, we assessed expression of cyclin D1, which ini-
tiates cell cycle entry in early G1 phase [22]. Increased
expression of cyclin D1 has been described previously in
rats with passive Heymann’s nephritis [7] and was con-
firmed in the present study. More important, CYC202,
at least transiently, decreased glomerular cyclin D1 ex-
pression in a significant manner. As discussed above, the
reduction of cyclin D1 in CYC202-treated rats may be
explained by effects of CYC202 on the “transcriptional
CDKs” (i.e., CDK7 and CDK9). Taken together, these
observations demonstrate that both low and high-dose
CYC202 reduced renal cell proliferation likely through
interference with CDK2 and possibly CDK7/CDK9. Fi-
nally, tubulointerstitial monocyte and macropahge counts
were reduced by high-dose CYC202, indicating an effect
on inflammatory cell responses. This phenomenon has
also been observed with CYC202 previously in rat mod-
els of nephrectomy (unpublished data) (Cyclacel Ltd.).
Again, this effect of CYC202 may be of interest for
the treatment of progressive renal disease, given that
anti-inflammatory actions, for example of mycopheno-
late mofetil, contributed to slower progression of renal
failure following 5/6-nephrectomy [36].
CONCLUSION
Our study demonstrates that it is safe to administer a
CDK antagonist for a 4-week period even in instances
where podocytes have in part entered the cell cycle and
are expressing CDK2 and other CDKs. CYC202 there-
fore continues to hold promise as a novel therapeutic
approach to proliferative glomerular disease.
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